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Background: Treatment with agonist anti-CD137 (4-1BB) immunostimulatory monoclonal antibodies elicits
complete tumor regressions in a number of transplanted hematological and solid malignancies in mice. Rejection is
mainly dependent on cytotoxic T lymphocytes (CTL) and IFNγ, although a role for NK cells and dendritic cells has
been observed in some tumor models. Rejection of EG7-derived thymomas has been shown to be CTL-dependent
but not NK-dependent.
Findings: In this therapeutic setting, we show that both the perforin-granzyme and FasL effector systems are
readily expressed by CD8+ T lymphocytes infiltrating the EG7 lymphomas which are undergoing rejection. Using
knock-out mice, we demonstrate that both effector cytolytic systems are involved in the execution of complete
immune rejections against EG7 established tumors. In accordance, EG7 tumor cells were susceptible in vitro to both
killing mechanisms acting in a synergistic fashion.
Conclusions: CD137-elicited rejection of EG7-derived tumors involves the interplay of at least two final effector
cytolytic mechanisms that act in cooperation.Findings
Introduction
CD137 agonists hold promise to augment antitumor im-
mune responses in a clinically significant fashion [1] and
two fully human monoclonal antibodies (mAbs) are cur-
rently undergoing clinical development (BMS-663513
and PFZ-05082566). Hematological malignancies are not
exception to the therapeutic effects of anti-CD137 mAbs
and activity has been reported on experimental models
of lymphoma, myeloma and mastocytomas [2-4]. The
mechanism of action depends mainly on cytolytic T lym-
phocytes (CTLs) since depletion of CD8β T cells com-
pletely abrogates the therapeutic effect [5]. The train of
events is complex and needs antigen priming by den-
dritic cells [5] and in some tumor models the participa-
tion of natural killer (NK) lymphocytes as observed in* Correspondence: imelero@unav.es
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distribution, and reproduction in any mediumselective depletion experiments [6]. More recently, evi-
dence has been published in the sense that anti-CD137
mAb enhances NK-mediated antibody-dependent cell-
mediated cytotoxicity (ADCC) [7,8], in a way that can be
exploited to enhance the antitumor activity of Herceptin
and Rituximab.
Evidence has been reported showing that activated
CD8+ tumor infiltrating lymphocytes (TILs) express
CD137 [9] and therefore are amenable to receive artifi-
cial costimulation by agonist anti-CD137 mAbs within
the malignant tissue microenvironment. The execution
of tumor rejection requires production of interferon
(IFN) γ by CTLs as demonstrated by neutralizing mAbs
[10] and with T cells derived from IFNγ-/- mice [10].
However, little is known about the final effector mecha-
nisms that mediate tumor cell killing. CTLs and NK
cells may kill using perforin-granzyme, FasL and TNF-
related apoptosis inducing ligand (TRAIL) as the execu-
tioner molecules [11-14]. Experiments performed in the
EG7 tumor model whose successful treatment does not
require NK cells [5] clearly show that both the cytolyticed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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synergistically involved in achieving complete rejections
of these lymphomas.
Results and discussion
Perforin, granzymes A and B and FasL are involved in
tumor rejection elicited by anti-CD137 mAbs
As previously published, tumors derived from the EG7
cell line (EL4 stably transfected with ovalbumin [15]) are
readily rejected following treatment with anti-CD137
mAb [5]. Treatment of 8-day established tumors with
1D8 mAb achieved complete rejections in six out of six
tumors, while the tumors in the control group lethally
progressed upon treatment with irrelevant rat IgG
(Figure 1A).
Experiments performed in perforin and granzyme A
and B triple knockout mice (PAB-/-) indicated that al-
though the therapeutic activity was reduced, a residual
beneficial effect remained, resulting in two out of six
complete rejections (Figure 1B). Conceivably, the FasL-
Fas route could also be involved in the execution ofFigure 1 Both perforin-granzyme and FasL pathways contribute to re
Wild type (A), perforin and granzyme A and B knockout (PAB-/-) (B) and Fas
and treated i.p. with 100 μg of control Rat IgG or anti-CD137 mAb on days
were sequentially measured 2-3 times per week. 6 mice per group were in
regression statistical method (Y= (MaxVol * exp(X-TimeO))/( 1 + exp((X-Tim
considered statistically significant.rejection by CTLs. Indeed, performing the experiment in
mice deficient for FasL (gld mice) also resulted in partial
loss of the immunotherapeutic activity of anti-CD137
mAb (Figure 1C). These results are interpreted in the
sense that pore-forming and granzyme entrance to ma-
lignant cells need to be complemented by FasL-mediated
induction of apoptosis in order to optimally achieve
tumor rejection.
Next, we explored if both killing mechanisms were
available in T cells at the site of tumor rejection. As can
be seen in Figure 2A, expression of intracellular
granzyme B is observed in a good number of CD8+ TILs
but not in the CD4+ counterparts (Figure 2A left). It is
of note that 6.7 ± 1.5% of CD8+ TILs stained positive
with H-2Kb-SIINFEKL tetramers clearly indicating the
presence of antigen specificity in the lymphocyte infil-
trate (Figure 2A right). Perforin expression in cytolytic
granules could not be explored due to the lack of satis-
factory mAbs for staining this protein in mice. FasL
(CD95L) was detected on the surface of both CD8+ and
CD4+ TILs (Figure 2B).jection of EG7 tumors upon treatment with anti-CD137 mAbs.
L-mutant gld (C) mice were injected s.c. with 5 × 105 EG7 tumor cells
8, 10, 12 and 14 after tumor cell challenge. Mean tumor diameters
cluded. Statistical comparisons were performed using a nonlinear
eO)/RateGrowth)) with GraphPad software. ***, P<0.001 were
Figure 2 The cytotoxic mechanisms responsible for EG7 tumor rejection are present in TILs after treatment with anti-CD137 mAb. Mice
were challenged s.c. with 5 × 105 EG7 cells and treated i.p. with anti-CD137 mAb on days 9 and 11. Two days later, tumors were removed and
TILs were analyzed by flow cytometry for intracellular granzyme B (A left) and percentage of H-2Kb-SIINFEKL tetramer+ cells (A right), surface FasL
(B), intracellular IFNγ (C) and surface CD107a (D) expression on gated CD8+ and CD4+ T lymphocytes. Histograms show CD8+ gated T cells that
come from a representative experiment. Grey histograms represent isotype-matched control antibody stainings and open histograms protein-
specific surface or intracellular stainings from representative cases. The insets in each histogram show the mean fluorescense intensity (MFI) after
subtracting the background staining or the percentage of CD107a positive cells (D) for the indicated immunostainings on CD8+ and CD4+ T cells
from individual tumors. The experiment was performed with 7-8 mice per group and mean±SEM is included in each histogram.
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production of IFNγ was required for tumor rejection
[10] and we observed that 15.7 ± 3.1% of CD8+ TILs
intracellularly express this cytokine without need for any
ex vivo restimulation of the intratumoral lymphocytes
(Figure 2C).
CD107a (LAMP.1) is a cytolytic granule transmem-
brane protein which emerges at killing synapses and re-
mains transiently on the plasma membrane of effector
cells. 7.8 ± 1.6% of CD8+ TILs were caught expressing
surface CD107a, thus demonstrating that they were ac-
tively degranulating at the time of tumor harvest
(Figure 2D). The fact that they are holding this “smoking
gun” tells of their active participation in cytotoxicity and
tumor rejection. In a separate experiment we were able
to gate onto T lymphocytes stained with CD8+ and H–2
Kb-SIINFEKL tetramers and analyze the expression of
effector molecules in this subset. As can be seen in
Additional file 1: Figure S1, these CTLs co-express
Granzyme B, IFNγ and CD107a.EG7 tumor cells are synergistically killed by the perforin-
granzyme and the FasL pathways
EG7 cells express surface Fas (Additional file 2: Figure S2A
inset) and hence anti-Fas agonistic antibody kills these
cells in 18 h as happens in Fas-transfected L1210 cells
but not in control untransfected cells. To assess the in-
volvement of these pathways in CTL killing of EG7
cells, anti-lymphocytic choriomeningitis virus (LCMV)
derived gp33 CTLs that are directed to a peptide
presented by H-2Kb were elicited by immunization with
LCMV-WE virus. Recovered CD8+ splenocytes from
immunized wild type (WT) mice 8 days after infections
showed 71% killing at 10:1 effector:target ratio on EG7
cells pulsed with the gp33 synthetic peptide (Figure 3A).
Under these experimental conditions optimal immunization
allows us to focus on the effector phase of CTL activity.
This activity was only reduced by about one half when im-
munized mice were deficient in PAB. Conversely, FasL
neutralization with MFL3 mAb during the 4 h cytotoxicity
experiment did not hamper killing. Interestingly, this anti-
Figure 3 Fas-FasL pathway and perforin-granzyme machineries
synergistically kill EG7 cell line. 5 × 104 EG7 cells were pre-pulsed
with LCMV gp33 peptide and cocultured in vitro for 4 h with 5 × 105
CD8+ T cells from LCMV immunized wild type (WT), perforin and
granzymes A and B knockout (PAB-/-) or gld mice in the presence or
absence of 1 μg/ml of FasL blocking antibody (MFL3). Cell death was
determined by annexin V staining in CD8 negative population by flow
cytometry. Ctr, control with target cells without gp33 peptide. Data in
the graphs are represented as mean±SEM of three independent
experiments. Statistical comparisons were performed using Student’s t
test with GraphPad software. *, P<0.05; **, P<0.01; ***, P<0.001; ns, no
significant. P<0.05 were considered significant.
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effector CTL from PAB-/- mice. CTLs from gld mice were
as effective as WT mice in accordance with the results with
FasL single blockade and, as expected, the MFL3 mAb did
not have any effect under these conditions, further
confirming the selectivity of the blocking mAb.
Therefore at least under these conditions, FasL and
the cytolytic granule machinery seem to synergistically
operate to bring about death of these lymphoma cells.
TRAIL engagement of its death promoting receptors
could have also been involved, but this was ruled out
since EG7 is not killed by 1μg of a recombinant form of
TRAIL that readily killed Jurkat cells as a positive con-
trol (Additional file 2: Figure S2B).
Materials and methods
Mice and cell lines
C57BL/6 wild type mice (6-8 weeks old) were purchased
from Harlan Laboratories. Mice deficient for perforin
and granzymes A and B (PAB-/- [16]) or with a mutation
in FasL (gld mice) were a kind gift of Markus Simon (Max-
Planck Institute of Immunobiology, Freiburg, Germany).
PAB-/- and gld mice were bred into the BL/6 background.
Animal experimentation followed FELASA guidelines and
approval of the Ethics Committee for Animal Experimen-
tation from CITA (2011-01) and University of Navarra
(study number 066/10). The murine thymoma cell line
EG7 was a kind gift from Dr. Claude Leclerc (Institut
Pasteur, Paris, France) and was authenticated using themaster cell banks by RADIL (Case number: 6592-2012).
Jurkat cells, L1210 and Fas-transfected L1210 have been
described [17,18].
In vivo tumor growth
5 × 105 EG7 cells were subcutaneously injected into the
flank of WT, PAB-/- or gld mice. Mice were intraperito-
neally treated with 100 μg/dose of anti-CD137 or control
Rat IgG on days 8, 10, 12 and 14 following tumor cell
inoculation. Rat IgG antibody was purchased from
Sigma-Aldrich and anti-CD137 clon 1D8 [2] was from
Bristol-Myers Squibb (Lawrenceville, NJ). Mice and
tumor size were monitored twice a week and mice were
sacrificed when the tumor size reached 300 mm2.
Preparation of cell suspensions from EG7 tumors
Tumors were excised and incubated for 15 minutes at
37°C in a solution containing Collagenase-D+DNase-I
(Roche) in RPMI. Afterwards, tumors were disrupted
mechanically and passed through a 70-μm cell strainer
(BD Falcon). Erythrocytes from cell suspensions were
lysed with potassium ammonium chloride lysing buffer.
Flow cytometry
Single-cell suspensions were pretreated with FcR-Block
(anti-CD16/32 clone 2.4G2). Anti-CD3ε, anti-CD8α,
anti-CD4, anti-FasL, anti-IFNγ, anti-granzymeB and
isotype Rat IgG and Hamster IgG isotype controls were
all purchased from Biolegend; anti-CD107a, anti-Fas,
mouse IgG isotype control and Apoptosis Detection Kit-I
were from BD Pharmingen; and anti-TRAIL mAb was
from eBioscience. H-2Kb-SIINFEKL tetramers were pur-
chased from Beckman Coulter. For intracellular stainings,
cells were fixed and permeabilized with Cytofix/Cytoperm
(BD Biosciences). Cells were studied with FACSCanto II
or FACSCalibur and were analyzed using FlowJo (TreeStar
software). Specific mean fluorescense intensity (MFI) and
percentage values in graphs are represented after subtrac-
tion of the control isotype-matched signal.
Fas and TRAIL induced cell death assays
105 cells were cultured with human recombinant
TRAIL, purified anti-Fas antibody (clone Jo2) or isotype
control (both from BD Biosciences) for 18 h. Human re-
combinant TRAIL functional on human and mouse re-
ceptors was produced in E.coli and purified as previously
described [19]. Cell death was analyzed by Annexin V
and 7-aminoactinomycin D (7-AAD) double staining.
Generation of ex vivo gp33-specific CD8+ cells
Mice were infected with 105 pfu LCMV-WE i.p. as de-
scribed [17]. On day eight after infection, CD8+ cells were
positively selected from spleen using anti-CD8-MicroBeads
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than 95%.
Ex vivo cytotoxicity assay
Target cells were pre-incubated with the LCMV-
immunodominant peptide gp33 (acquired from Neosystem
Laboratory) and effector CD8+ cells were stained with
CellTracker Green (Invitrogen). Effector and target cells
were incubated at a ratio of 10:1 (effector:target) during
4 hours. In certain experiment anti-FasL blocking antibody
(clone MFL3) (BD Biosciences) was added during the 4 h
cytotoxicity assay. Gated CellTracker Green-negative
targets were analyzed for annexin V and 7-AAD double
staining.
Conclusions
As a whole, we have demonstrated using a tumor model
amenable to successful immunotherapy with anti-CD137
mAb that the FasL and perforin-granzyme killing ma-
chineries act non-redundantly and synergistically to exe-
cute complete tumor rejections upon therapy with
agonist anti-CD137 mAb.
Additional files
Additional file 1: Figure S1. Experiments as in figure 2 but in this case
TILs from five EG7 tumors were pooled and stained with the H-2Kb
SIINFEKL tetramer. Gated CD8+ Tetramer+ T lymphocytes were analyzed
for expression of the indicated effector molecules as depicted in the
corresponding histograms.
Additional file 2: Figure S2. The EG7 cell line is susceptible to being
killed by anti-Fas antibody but not by recombinant TRAIL. (A) 1 × 105
EG7 cells per well were cultured 18 h with 5 μg/ml of soluble anti-Fas
antibody. Cell death was determined by annexin V staining by flow
cytometry. The inset histogram shows surface Fas expression by the EG7
cell line. The gray histogram represents isotype-matched control antibody
and open histogram Fas-specific surface staining. (B) EG7 or positive
control Jurkat cells were incubated for 18 hours with 0 to 1 μg/ml
human recombinant TRAIL (hrTRAIL) and cell death was analyzed by flow
cytometry using 7-AAD and annexin V staining. Dead cells are
represented as the percentage of both Annexin V single positive and
Annexin V/7-AAD double positive. Data in the graphs are represented as
mean±SEM of three independent experiments. Statistical comparisons
were performed using Student’s t test with GraphPad software. *, P<0.05;
**, P<0.01; ***, P<0.001; ns, no significant. P<0.05 were considered
significant.
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